Bayer Aktiengesellschaft

Aicuris Gmbh + Co. Kg.

Bayer Healthcare LLC

Bayer Pharma Aktiengesellschaft

Other

Bayer Intellectual Property Gmbh

Bayer Pharmaceuticals Corporation

Olaf Weber

Tobias Schlapp

Angela Siegling

Karl-Heinz Schlemmer

Siegfried Goldmann

Wolfgang Bender

Peter Eckenberg

Hans-Dieter Volk

Erwin Graef

Andrew Allan Mercer

Stephen Bruce Fleming

Karl Deres

Andreas Knorr

Hilmar Bischoff

Alexandros Vakalopoulos

Carsten Schmeck

Martin Hendrix

Udo Schneider

Arnold Paessens

Kerstin Henninger

Claudia Hirth-Dietrich

Judith Baumeister

Uday R Khire

Gerald Kleymann

Stephen Boyer

Ulrich Betz

Maria Niewöhner

Volkhart Li

Davoud Asgari

Michael H&auml;rter

Chunguang Wang

Gabriele Handke

Sabine Hallenberger

Axel Jensen

Michael Thutewohl

Barry Hart

Mark Lynch

Jianxing Shao

Gudrun Theiss

Xiao-Gao Liu

J&ouml;rg Trappe

J&uuml;rgen Reefschl&auml;ger

Sonja Maria Tennagels

Dhanapalan Nagarathnam

Rüdiger Fischer

Jurgen Stoltefuss

Klemens Lustig

Jörg Keldenich

Paul Naab

Marcus Bauser

Ulrich Niew&ouml;hner

Nils Burkhardt

Jens-Kerim Ergüden

Dietmar Flubacher

Heike Gielen-Haertwig

J&ouml;rg Keldenich

Daniela Paulsen

Karl Ziegelbauer

Thomas Krämer

J&uuml;rgen Stoltefuss

Ulrich Niewöhner

J&ouml;rn St&ouml;lting

Jörn Stölting

Jürgen Stoltefuss

Maria Theresia Niewohner, Legal Representative

R&uuml;diger Fischer

Michael Schauer

Lei Wang

Stefan Lottmann

Lei Zhang

Martina Wuttke

Mark Miglarese

Sonja Maria Friederichs

Helga Ruebsamen-Schaeff

Siegfired Goldmann

Thomas Kr&auml;mer

Amar Kureishi

Stefan Lettmann

Gerhard Hunsmann

Christiane Stahl-Hennig

Andreas Meyerhans

Dhanaphalan Nagarathnam

Andrea Sewing

Thorsten-Oliver Repp

Alexandra Schuetz

Arnold Paeβens

Donald Bankston

Jürgen Stoltefuβ

Sonja-Maria Friederichs

The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.

Combination of regorafenib and acetylsalicylic acid for treating cancer

The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.

Recombinant proteins of parapdxvirus ovis and pharmaceutical compositions therefrom

[object Object]

Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom

The present invention relates to the use ofin combination with other agents for the treatment of viral diseases, and in particular HIV infections and AIDS. The invention also relates to methods for producing medicaments based on combinations ofand other antiviral agents, and to such medicaments. In particular, the invention relates to the use ofin combination with agents of the kind used for antiretroviral therapy and highly active antiretroviral therapy (HAART).

Parapoxviruses in combination with other antiviral agents for the treatment of viral diseases

The present invention relates to substituted chromanol derivatives, to processes for their preparation, to their use on their own or in combination for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.

Substituted chromanol derivatives and their use

The present application relates to a novel tetrahydroquinoline derivative, to a process for its preparation, to its use on its own or in combination for treating and/or preventing diseases and to its use for preparing medicaments, in particular as an inhibitor of the cholesterol ester transfer protein (CETP) for the treatment and/or prevention of cardiovascular disorders, in particular hypolipoproteinaemias, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, hypercholesterolaemias and arteriosclerosis.

Chemical compound and its use

The invention relates to a method for the production of a pharmaceutical composition for treating cancer by combiningwith at least one anticancer agent. The invention furthermore relates to a method for treating a patient afflicted with cancer comprising the administration ofin combination with at least one anticancer agent.

Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Disclosed are compounds and derivatives thereof their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors

A process for the preparation of various quinazoline compounds which are useful as Rho-Kinase inhibitors, and thus having utility in the treatment of hypertension and other indications.

Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof

The invention relates to compounds of the formule 

3,5-Difluoropyridines

The present invention relates to novel compounds, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.

Thiazolyl amide derivatives

Novel dihydropyrimidines and combinations thereof with other antiviral agents, suitable for combating HBV infections.

Medicaments against viral diseases

The present invention relates to pyrrolo[2.1-a]dihydroisoquinolines which are inhibitors of phosphodiesterase 10a and can be used for combating cancer.

Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors

Dihydropyrimidines

Growing community of inventors

Wuelfrath, Germany

Olaf Weber